|
|
|
11.06.26 - 00:01
|
Camurus provides regulatory update on the US NDA for CAM2029 (Oclaiz™) in acromegaly (Cision)
|
|
|
Lund, Sweden — 10 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (Oclaiz™), octreotide extended-release injection, for the treatment of patients with acromegaly.
The CRL relates to the observations from the September 2024 cGMP inspection at a third-party manufacturer. FDA has indicated that satisfactory resolution of these observations, which could include a reinspection of the facility, is required before the NDA can be approved. FDA...
|
|
|
02.06.26 - 08:57
|
Eli Lilly: Es geht Schlag auf Schlag – nächster Deal mit Camurus (Der Aktionaer)
|
|
|
Der US-amerikanische Pharma-Riese Eli Lilly bleibt auf Shopping-Tour. Neben zwei Lizenzdeals in Asien konnte das Unternehmen auch eine erweiterte Partnerschaft mit der schwedischen Camurus einfädeln. Für die Skandinavier ist die Erweiterung der Kollaboration vor allem aus finanzieller Sicht von enormer Bedeutung....
|
|
|
|
|
01.06.26 - 17:39
|
Camurus announces expansion of Lilly collaboration (PR Newswire)
|
|
|
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's......
|
|
|
01.06.26 - 17:36
|
Camurus announces expansion of Lilly collaboration (PR Newswire)
|
|
|
LUND, Sweden, June 1, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company ("Lilly") has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly's......
|
|
|
|
|
28.05.26 - 19:01
|
Resolutions at the annual general meeting 2026 in Camurus (Cision)
|
|
|
Lund, Sweden — 28 May 2026 — Camurus AB's (CAMX) annual general meeting 2026 was held today, Thursday 28 May, at The Loop in Lund.
The annual general meeting adopted the presented income statements and balance sheets as well as the remuneration report prepared by the Board and granted discharge of liability to Board members and the CEO. In addition, the following main resolutions were passed.
Election of Board members and auditor
Per Olof Wallström, Hege Hellstrøm, Jakob Lindberg, Stefan Persson, Erika Söderberg Johnsson, Fredrik Tiberg, Elisabeth Björk and Robert McQuade were re-...
|
|
|
21.05.26 - 10:01
|
Camurus to present at Jefferies Global Healthcare Conference (Cision)
|
|
|
Lund, Sweden — 21 May 2026 — Camurus (NASDAQ STO: CAMX) will participate in the Jefferies Global Healthcare Conference in New York, 2–4 June, 2026. President and CEO Fredrik Tiberg will present on 3 June at 10.55 pm CET, providing an update on the company's recent developments.
A webcast of the presentation will be available through the following link:
https://event.summitcast.com/view/NgCqua4VVQjq9ibVWHVWca/guest_book?session_id=iX2ZMLifXKSubp3gHo3gjg
For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com (mir@camurus.com)...
|
|
|
|
|
|
|
12.05.26 - 07:00
|
Camurus′ Interim Report January-March 2026 (Cision)
|
|
|
“Q1 performance on track for full-year guidance”
Summary first quarter 2026
January - March
· Total revenues decreased 5% (increased 3% at CER[1]) to SEK 533 (558) million
· Product sales decreased 12% (6% at CER[1]) to SEK 426 (485) million
· Royalties increased 44% (59% at CER[1]) to SEK 106 (74) million
· Operating result decreased 30% (15% at CER[1]) to SEK 168 (239) million
· Profit before tax decreased 28% (14% at CER[1]) to SEK 184 (254) million
· The cash position at the end of the quarter was SEK 3.9 (2.9) billion
· FDA accepted the Oclaiz™ NDA for...
|
|
|
29.04.26 - 10:06
|
Camurus Annual Report for 2025 (Cision)
|
|
|
Lund, Sweden — 29 April 2026 — Camurus (CAMX) today announces that the Annual Report for 2025 now is available at the company's website: www.camurus.com, and as an attachment to this press release. The Swedish version of the Annual Report is also available on the website in European Single Electronic Format (ESEF).
In 2025, Camurus achieved substantial growth of revenue and profitability, while enhancing patient access to effective treatments, expanding the commercial presence, and progressing a pipeline positioned to drive long-term growth.
The Annual Report also includes Camurus'...
|
|
|
24.04.26 - 08:00
|
Notice of annual general meeting 2026 in Camurus AB (publ) (Cision)
|
|
|
The shareholders of Camurus AB (publ), Reg. No 556667-9105, are hereby invited to the Annual General Meeting (“AGM”) on 28 May 2026 at 17.00 CEST at The Loop, Rydbergs torg 4, in Lund, Sweden. Registration for the AGM begins at 16.30 CEST.
The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the AGM also by postal voting in accordance with the regulations in Camurus' Articles of Association.
Right to participate and notification
A) Participation in the meeting room
A person who wishes to attend the meeting room in person or...
|
|
|
31.03.26 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 31 March 2026 — During March 2026, 54,450 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,450.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,934,734 corresponding to 59,934,734 votes. As of 31 March 2026, the total number of shares in Camurus amounts to 59,989,184 corresponding to 59,989,184...
|
|
|
27.02.26 - 15:30
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 27 February 2026 — During February 2026, 54,550 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 54,550.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,880,184 corresponding to 59,880,184 votes. As of 27 February 2026, the total number of shares in Camurus amounts to 59,934,734 corresponding to...
|
|
|
|
|
17.02.26 - 08:00
|
Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer (Cision)
|
|
|
Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed as Camurus' Chief Corporate Development Officer (CCDO) and member of the executive management team, effective 23 March, 2026.
Jane brings more than 20 years of experience from senior positions at Novo Nordisk and AstraZeneca within Business and Corporate Development, with a strong track record of driving strategic licensing and M&A transactions, integration processes and alliance management. Most recently, she had the position as Corporate VP in Global Business...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
